Drug Profile
CTL 102-tretazicar
Alternative Names: CTL 102; CTL-102-GDEPT; CTL102/CB1954; NTR-GDEPTLatest Information Update: 10 Jul 2007
Price :
$50
*
At a glance
- Originator University of Birmingham
- Developer Innovata
- Class Antineoplastics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Head and neck cancer; Liver cancer; Prostate cancer
Most Recent Events
- 10 Jul 2007 Discontinued - Phase-II for Head and neck cancer in United Kingdom (Intratumoural)
- 10 Jul 2007 Discontinued - Phase-II for Liver cancer in United Kingdom (Intratumoural)
- 10 Jul 2007 Discontinued - Phase-II for Prostate cancer in United Kingdom (Intratumoural)